Blind World

AMD Photodynamic Therapy Research.
Study of eyes of patients who have received Photodynamic Therapy.

May 31, 2004.

Emory Eye Center.
Atlanta, Georgia.

The Emory Eye Center is located in Atlanta, Georgia on the Emory University School of Medicine campus and is currently in the top ten NIH funded eye research institutions in the U.S. The Eye Center's L.F. Montgomery Ophthalmic Pathology Laboratory has been designated to study the eyes of patients who have received Photodynamic Therapy. The purpose of the study is to determine what effect the PDT treatments have on the abnormal blood vessels and scar tissue that degrade the macula. The only way to determine the effectiveness of PDT is by studying the eyes of post-mortem donors. Why Donate to Science? Donated eyes can help scientists to research ways to improve the treatment of AMD.

A gift of your eyes at the time of your death can help scientists improve treatments for future generations of people who suffer with AMD. Without human donors who have received the PDT treatment, it is very difficult to determine the efficacy of PDT. If you think you may be interested and need

more information, you may contact the Emory Eye Center at (800)266-0400.


> The focus of our research in the last year has been to Dr. Robert D'Amato, a research scientist at Harvard University in Boston. Dr. D'Amato discovered a natural compound, Cyto E, that would act as an inhibitor for new blood vessel growth behind the eye. Not only is this compound important because it is "natural" but he is also using a minimally invasive drug delivery system. This delivery system targets the eye area without the trauma of an injection into the eye. The delivery system uses a polymer sponge, implanted in the lower eyelid, which is able to be programmed to deliver the medication specifically to the eye. This project is in the phase 1/11 stage for FDA approval.

> Our recent research proposal is from Dr. Alan Marmorstein, a research scientist from the University of Arizona. He will use an animal model to show that microcurrent stimulation can induce a growth factor that will stimulate the revival of photoreceptor cells. As this research progresses, we hope to also show visual acuity benefits in patients through patient trials with the Ophthalmology Department at the University of Arizona.

>Using the premise that microcurrent stimulation increases circulation, we hope to be working with the University of Pennsylvania to prove that MCS does increase blood flow and blood volume in the retina/macula region. This research is very valuable and is the closest means to a therapy for the "dry form" of macular degeneration that will in turn affect the number of patients that progress to the more severe "wet form" of the disease.

End of article.

Go to ...

Top of Page.

Previous Page.

List of Categories.

Home Page.

Blind World Website
Designed and Maintained by:
George Cassell
All Rights Reserved.

Copyright Notice
and Disclaimer.